278 related articles for article (PubMed ID: 27497344)
41. Bilateral subfoveal neurosensory retinal detachment associated with MEK inhibitor use for metastatic cancer.
McCannel TA; Chmielowski B; Finn RS; Goldman J; Ribas A; Wainberg ZA; McCannel CA
JAMA Ophthalmol; 2014 Aug; 132(8):1005-9. PubMed ID: 24852144
[TBL] [Abstract][Full Text] [Related]
42. Therapeutic efficacy of combined BRAF and MEK inhibition in metastatic melanoma: a comprehensive network meta-analysis of randomized controlled trials.
Mai R; Zhou S; Zhong W; Rong S; Cong Z; Li Y; Xie Q; Chen H; Li X; Liu S; Cheng Y; Huang Y; Zhou Y; Zhang G
Oncotarget; 2015 Sep; 6(29):28502-12. PubMed ID: 26143635
[TBL] [Abstract][Full Text] [Related]
43. From targeted monotherapy to combined BRAF-MEK inhibitors and integrated genome analysis for melanoma treatment.
Roukos DH; Papaloukas C; Tzaphlidou M
Future Oncol; 2013 Jan; 9(1):5-8. PubMed ID: 23252557
[No Abstract] [Full Text] [Related]
44. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
[TBL] [Abstract][Full Text] [Related]
45. Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma.
Dika E; Patrizi A; Ribero S; Fanti PA; Starace M; Melotti B; Sperandi F; Piraccini BM
Eur J Dermatol; 2016 Jun; 26(3):232-9. PubMed ID: 27019511
[TBL] [Abstract][Full Text] [Related]
46. Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma.
Seremet T; Lienard D; Suppa M; Trepant AL; Rorive S; Woff E; Cuylits N; Jansen Y; Schreuer M; Del Marmol V; Neyns B
Melanoma Res; 2015 Apr; 25(2):180-3. PubMed ID: 25643238
[TBL] [Abstract][Full Text] [Related]
47. [Melanoma].
Uhara H
Gan To Kagaku Ryoho; 2016 Apr; 43(4):404-7. PubMed ID: 27220785
[TBL] [Abstract][Full Text] [Related]
48. BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy.
Sloot S; Zager JS; Kudchadkar RR; Messina JL; Benedict JJ; Gonzalez RJ; DeConti R; Turner LM; McCardle T; Smalley KS; Weber JS; Sondak VK; Gibney GT
Melanoma Res; 2016 Feb; 26(1):83-7. PubMed ID: 26731560
[TBL] [Abstract][Full Text] [Related]
49. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
Vanneste L; Wolter P; Van den Oord JJ; Stas M; Garmyn M
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):61-8. PubMed ID: 24661317
[TBL] [Abstract][Full Text] [Related]
50. [Update on BRAF and MEK inhibitors in the treatment of malignant melanoma].
Gutzmer R
J Dtsch Dermatol Ges; 2015 May; 13(5):485-7. PubMed ID: 25918105
[No Abstract] [Full Text] [Related]
51. Mitogen-activated protein kinase inhibitor-associated retinopathy (MEKAR). A clinical case.
Buenasmañanas-Maeso M; Gutiérrez-Montero Ó; Reche-Sainz JA; Badillo Arcones E; Monja-Alarcón N; Toledano-Fernández N
Arch Soc Esp Oftalmol (Engl Ed); 2022 May; 97(5):286-289. PubMed ID: 35526952
[TBL] [Abstract][Full Text] [Related]
52. Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma.
King JW; Nathan PD
Future Oncol; 2014; 10(9):1559-70. PubMed ID: 25145427
[TBL] [Abstract][Full Text] [Related]
53. Changes in tumor morphology and cyclin-dependent kinase inhibitor expression in metastatic melanoma treated with selective second-generation BRAF inhibitor.
Curry JL; Falchook GS; Hwu WJ; Torres-Cabala CA; Duvic M; Tetzlaff MT; Prieto VG
Am J Dermatopathol; 2013 Feb; 35(1):125-8. PubMed ID: 22878367
[TBL] [Abstract][Full Text] [Related]
54. Improved survival with MEK inhibition in BRAF-mutated melanoma.
Flaherty KT; Robert C; Hersey P; Nathan P; Garbe C; Milhem M; Demidov LV; Hassel JC; Rutkowski P; Mohr P; Dummer R; Trefzer U; Larkin JM; Utikal J; Dreno B; Nyakas M; Middleton MR; Becker JC; Casey M; Sherman LJ; Wu FS; Ouellet D; Martin AM; Patel K; Schadendorf D;
N Engl J Med; 2012 Jul; 367(2):107-14. PubMed ID: 22663011
[TBL] [Abstract][Full Text] [Related]
55. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
Owen JL; Lopez IE; Desai SR
J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
[TBL] [Abstract][Full Text] [Related]
56. Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
Welsh SJ; Rizos H; Scolyer RA; Long GV
Eur J Cancer; 2016 Jul; 62():76-85. PubMed ID: 27232329
[TBL] [Abstract][Full Text] [Related]
57. Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition.
Gowrishankar K; Snoyman S; Pupo GM; Becker TM; Kefford RF; Rizos H
J Invest Dermatol; 2012 Jul; 132(7):1850-9. PubMed ID: 22437314
[TBL] [Abstract][Full Text] [Related]
58. Encorafenib and Binimetinib: First Global Approvals.
Shirley M
Drugs; 2018 Aug; 78(12):1277-1284. PubMed ID: 30117021
[TBL] [Abstract][Full Text] [Related]
59. Cardiac Effects of BRAF and MEK Inhibitors: Mechanisms and Clinical Management.
Courand PY; Berger M; Bouali A; Harbaoui B; Lantelme P; Dalle S
Curr Oncol Rep; 2022 Mar; 24(3):265-271. PubMed ID: 35102484
[TBL] [Abstract][Full Text] [Related]
60. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]